Nifty
Sensex
:
:
12010.20
40342.67
113.40 (0.95%)
-201.70 (-0.50%)

Pharmaceuticals & Drugs - Global

Rating :
58/99  (View)

BSE: 524816 | NSE: NATCOPHARM

929.00
4.60 (0.50%)
21-Oct-2020 | 1:34PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  929.00
  •  936.45
  •  917.90
  •  924.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  170207
  •  1581.22
  •  996.00
  •  402.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,832.20
  • 38.22
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,082.10
  • 0.73%
  • 4.35

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.91%
  • 1.53%
  • 14.86%
  • FII
  • DII
  • Others
  • 19.32%
  • 12.91%
  • 2.47%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.34
  • 10.91
  • -4.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 20.46
  • 16.40
  • -8.90

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.02
  • 24.01
  • -12.85

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.73
  • 26.16
  • 20.75

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.28
  • 5.58
  • 4.04

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.71
  • 21.58
  • 15.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
563
492
14%
455
456
0%
482
557
-13%
486
544
-11%
Expenses
392
301
30%
326
307
6%
354
348
1%
351
323
9%
EBITDA
171
191
-11%
128
148
-13%
129
208
-38%
134
220
-39%
EBIDTM
30%
39%
14%
33%
27%
37%
28%
41%
Other Income
19
21
-11%
22
31
-28%
31
23
32%
33
40
-17%
Interest
4
6
-43%
4
5
-33%
5
6
-16%
6
5
24%
Depreciation
28
22
27%
30
22
41%
25
21
23%
22
20
8%
PBT
158
184
-14%
117
152
-23%
129
205
-37%
139
235
-41%
Tax
36
41
-12%
24
32
-27%
24
45
-46%
22
54
-60%
PAT
122
143
-14%
93
120
-23%
104
159
-34%
118
182
-35%
PATM
22%
29%
7%
26%
22%
29%
24%
33%
EPS
6.70
7.84
-15%
5.12
6.61
-23%
5.73
8.74
-34%
6.46
9.97
-35%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,986
1,915
2,094
2,185
2,020
1,141
825
739
661
524
460
Net Sales Growth
-3%
-9%
-4%
8%
77%
38%
12%
12%
26%
14%
 
Cost Of Goods Sold
5,034
354
354
411
599
341
242
233
243
203
186
Gross Profit
-3,048
1,561
1,740
1,774
1,421
800
583
506
418
321
274
GP Margin
-153%
81%
83%
81%
70%
70%
71%
68%
63%
61%
60%
Total Expenditure
1,424
1,332
1,300
1,256
1,337
869
612
560
511
414
369
Power & Fuel Cost
-
62
60
56
50
44
43
45
39
27
21
% Of Sales
-
3%
3%
3%
2%
4%
5%
6%
6%
5%
5%
Employee Cost
-
375
356
326
243
190
137
113
102
80
66
% Of Sales
-
20%
17%
15%
12%
17%
17%
15%
15%
15%
14%
Manufacturing Exp.
-
243
208
183
141
105
73
77
65
43
40
% Of Sales
-
13%
10%
8%
7%
9%
9%
10%
10%
8%
9%
General & Admin Exp.
-
133
130
106
88
73
64
56
39
32
27
% Of Sales
-
7%
6%
5%
4%
6%
8%
8%
6%
6%
6%
Selling & Distn. Exp.
-
98
137
137
143
92
37
26
15
19
13
% Of Sales
-
5%
7%
6%
7%
8%
5%
4%
2%
4%
3%
Miscellaneous Exp.
-
66
55
38
72
24
15
10
7
10
13
% Of Sales
-
3%
3%
2%
4%
2%
2%
1%
1%
2%
3%
EBITDA
562
583
795
928
683
273
213
179
150
109
91
EBITDA Margin
28%
30%
38%
42%
34%
24%
26%
24%
23%
21%
20%
Other Income
105
107
130
40
14
10
15
17
12
9
5
Interest
19
22
19
15
18
23
32
37
26
23
14
Depreciation
106
100
81
66
54
51
47
30
22
16
16
PBT
543
569
825
887
624
209
149
129
114
80
65
Tax
106
111
182
192
140
53
4
31
36
21
13
Tax Rate
19%
19%
22%
22%
22%
25%
3%
24%
36%
26%
20%
PAT
437
461
644
696
486
157
135
103
72
60
54
PAT before Minority Interest
440
458
642
695
485
156
130
98
66
58
52
Minority Interest
2
3
2
1
1
1
4
5
6
1
2
PAT Margin
22%
24%
31%
32%
24%
14%
16%
14%
11%
11%
12%
PAT Growth
-28%
-28%
-7%
43%
209%
17%
31%
43%
21%
11%
 
EPS
24.01
25.29
35.37
38.21
26.67
8.62
7.39
5.64
3.94
3.27
2.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
3,774
3,489
3,072
1,649
1,296
846
726
534
474
352
Share Capital
36
36
37
35
35
33
33
31
31
28
Total Reserves
3,714
3,422
3,011
1,599
1,251
813
693
502
442
324
Non-Current Liabilities
118
83
47
38
28
119
151
191
171
160
Secured Loans
0
0
0
0
0
94
92
136
134
125
Unsecured Loans
1
0
0
0
0
3
3
2
0
0
Long Term Provisions
90
71
32
22
12
10
11
9
7
9
Current Liabilities
685
729
592
626
493
414
312
345
259
193
Trade Payables
255
217
269
263
276
125
110
106
92
77
Other Current Liabilities
96
110
133
127
114
119
102
90
82
44
Short Term Borrowings
315
386
173
222
98
169
99
148
82
72
Short Term Provisions
19
16
16
15
5
1
2
1
3
1
Total Liabilities
4,588
4,303
3,715
2,318
1,822
1,384
1,196
1,080
905
707
Net Block
1,584
1,227
1,019
833
710
710
645
583
320
270
Gross Block
2,149
1,696
1,408
1,159
983
940
820
727
440
374
Accumulated Depreciation
564
469
389
326
273
226
171
141
117
104
Non Current Assets
2,262
1,956
1,584
1,230
985
901
828
750
612
460
Capital Work in Progress
518
638
480
336
212
129
124
106
164
76
Non Current Investment
84
20
8
0
0
2
2
2
62
62
Long Term Loans & Adv.
72
69
75
60
62
57
54
57
66
51
Other Non Current Assets
4
2
2
0
1
4
3
3
0
1
Current Assets
2,326
2,347
2,131
1,087
837
483
368
330
293
247
Current Investments
29
149
68
32
22
0
0
1
1
1
Inventories
558
529
438
349
357
220
181
146
110
102
Sundry Debtors
551
506
638
475
262
192
119
130
95
71
Cash & Bank
66
280
184
36
45
13
11
11
37
32
Other Current Assets
1,122
100
53
26
151
57
57
43
50
41
Short Term Loans & Adv.
1,030
784
750
170
125
41
52
39
42
37
Net Current Assets
1,640
1,618
1,539
461
344
69
56
-14
33
54
Total Assets
4,588
4,303
3,715
2,318
1,822
1,384
1,196
1,080
905
707

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
417
669
464
346
112
93
144
61
65
37
PBT
569
825
887
624
209
134
129
102
80
65
Adjustment
54
14
76
100
90
68
66
49
37
39
Changes in Working Capital
-98
9
-295
-253
-141
-86
-16
-67
-28
-48
Cash after chg. in Working capital
525
848
668
472
158
116
179
84
89
55
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-108
-179
-205
-126
-46
-24
-35
-23
-24
-18
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-167
-612
-1,116
-299
-176
-115
-109
-107
-127
-89
Net Fixed Assets
-336
-436
-392
-299
-304
-100
-100
-102
-152
-71
Net Investments
53
-95
-55
-1
37
-42
-11
-3
-4
8
Others
116
-81
-668
1
91
28
2
-2
28
-25
Cash from Financing Activity
-251
-51
651
-48
154
29
-35
26
63
77
Net Cash Inflow / Outflow
0
6
-1
-1
91
7
0
-20
1
25
Opening Cash & Equivalents
28
22
24
24
-164
10
10
35
32
7
Closing Cash & Equivalent
20
28
22
24
-74
12
10
10
35
32

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
206
189
165
94
74
51
219
170
152
125
ROA
10%
16%
23%
23%
10%
10%
9%
7%
7%
8%
ROE
13%
20%
30%
33%
15%
17%
16%
13%
14%
16%
ROCE
15%
24%
35%
39%
18%
16%
18%
16%
16%
16%
Fixed Asset Turnover
1.07
1.35
1.72
1.93
1.23
0.95
0.96
1.14
1.30
1.27
Receivable days
94
100
92
65
70
68
61
61
57
50
Inventory Days
96
84
65
62
89
87
80
70
73
70
Payable days
66
73
81
78
85
73
74
73
79
84
Cash Conversion Cycle
124
111
76
49
74
82
67
58
51
37
Total Debt/Equity
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
0.55
0.62
Interest Cover
27
44
59
35
10
5
5
5
4
6

News Update


  • Natco Pharma aims to launch around 10 new products every year in Indian market
    16th Oct 2020, 09:15 AM

    It has also some interesting filings and high-value launches in its international markets in the coming years

    Read More
  • Natco Pharma aims to diversify product portfolio in domestic market
    21st Sep 2020, 17:15 PM

    The company is planning for new product launches in the non-oncology segment to mitigate the impact of the Hepatitis-C market decline

    Read More
  • Natco Pharma - Quarterly Results
    12th Aug 2020, 14:26 PM

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.